mitapivat tablets
for oral use Initial U.S. Approval: 2022

Pyrukynd (mitapivat) tablets to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase deficiency, an inherited disorder that causes premature red blood cell destruction.

Facts about mitapivat tablets

Approval Date: 2/17/2022
Proprietary Name: Pyrukynd
Active Ingredient(s): mitapivat
FDA-approved use: To treat hemolytic anemia in pyruvate kinase deficiency
Dosage Form: Tablet
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “mitapivat tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.